The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Zhipeng WangSha ZhuJinge ZhaoLing NieXueqin ChenMengni ZhangNi ChenGuangxi SunJunru ChenYuchao NiJindong DaiZhenhua LiuRonggui TaoXingming ZhangXudong ZhuHaoran ZhangJiayu LiangZilin WangBen HePeng-Fei ShenHao ZengPublished in: The Prostate (2021)
Compared to docetaxel, abiraterone exhibited better efficacy in patients with IDC-P of either pattern. However, IDC-P pattern 2 responded unsatisfactorily to either abiraterone or docetaxel therapy. Novel therapeutic strategies for IDC-P pattern 2 need further investigations.